N. Lawrence Edwards, MD, MACP, MACR

WASHINGTON — A phase 1/2 study of CD19 chimeric antigen receptor T-cell therapy in lupus and other autoimmune diseases demonstrated significant response with minimal toxicities, according to data presented at ACR Convergence 2024.

SAN DIEGO — Sodium-glucose cotransporter-2 inhibition may reduce the risk for gout by as much as 40% to 60% among certain patients with type 2 diabetes treated with metformin, according to data presented at ACR Convergence 2023.

The risks for major adverse cardiac events and venous thromboembolism in patients with rheumatoid arthritis did not significantly differ between those receiving Janus kinase inhibitors or adalimumab, according to data.